Project Grant R01CA291437
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$436K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $645,012 to the University of North Carolina at Chapel Hill (UNC-CH) to study how the Epstein-Barr virus (EBV) upregulates the FAM72A gene, which contributes to the development of EBV-driven non-Hodgkin lymphoma (NHL) subtypes. The 5-year project, running from Sep 2024 to Aug 2029, will address the mechanisms by which EBV's upregulation of FAM72A leads to the formation...
The National Cancer Institute (NCI) awarded a $183,044 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Regents of the University of Michigan. The grant, titled "Resolving Viral Oncoprotein Control of Terminal Cell Fates to Limit Epstein-Barr Virus-Driven Lymphoproliferation," aims to investigate how the Epstein-Barr virus (EBV) oncoproteins EBNA3A and EBNA3C coordinate with the cellular epigenetic regulator EZH2 to promote pathogenic lymphoproliferation....
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $601,309 to the University of Florida to conduct research on understanding viral mechanisms that could inform oncolytic therapies for Epstein-Barr virus (EBV)-associated lymphomas in people living with HIV. The key focus of the research is to identify core upstream mechanisms that disrupt silencing of the EBV gene...
This $691,788 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports research at the University of Pittsburgh to investigate the role of the ASB13 protein in regulating the Epstein-Barr virus (EBV) life cycle. The research aims to determine the mechanisms by which ASB13 inhibits SYK signaling and viral protein stability to restrict EBV lytic replication, as well...
This Project Grant award of $157,000 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to unveil a novel mechanism of oncovirus-induced carcinogenesis. The primary awardee, Rutgers, The State University of New Jersey, will conduct long-read sequencing on hepatitis B virus (HBV)-positive tumors and cell lines to fully map HBV integrations and identify HBV integration-bridged chromosomal translocation events. This research aims to validate...
This Project Grant award of $1,527,730 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a longitudinal study among African Americans to investigate the role of Epstein-Barr virus (EBV) and molecular mimicry as potential causes of multiple sclerosis (MS). The study will leverage pre-diagnostic serum samples and clinical data from over 10 million active duty U.S. military personnel to assess antibody responses...
This $420,335 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding the role of lytic viral gene expression in the development and maintenance of oncogenic gammaherpesvirus-associated cancers. The University of Arkansas for Medical Sciences (UAMS) is leading this 2-year research project to test the hypothesis that lytic gene expression is...
This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico Health Sciences Center (UNM HSC) to conduct research on the mechanisms of papillomavirus tumor regression induced by MEK signaling inhibition. The 5-year project aims to understand how MEK inhibition reduces expression of the HPV oncogenes E6 and E7, leading to diminished keratinocyte proliferation and activation of innate immune responses to...
The National Cancer Institute (NCI) awarded a $162,080 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Johns Hopkins University. The grant supports a study to visualize B cell infiltration and aggregation within the tumor microenvironment. Specifically, the study uses transgenic mouse models and intravital microscopy to investigate how high endothelial venules facilitate B cell entry into tumors and the formation of tertiary lymphoid structures,...